The Frequency of Antithrombotic Therapy in Management of Non-Valvular Atrial Fibrillation in Hospitalized Patients

Document Type : Original Article (s)

Authors

1 Cardiologist, Al Zahra Hospital, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Assistant Professor, Department of Internal Medicine, Al Zahra Hospital, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Associate Professor, Department of Internal Medicine, Al Zahra Hospital, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Medical Student, Department of Internal Medicine, Al Zahra Hospital, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Atrial fibrillation is the most common sustained arrhythmia and is associated with poor outcomes, including stroke. The ability of anticoagulation therapy to reduce the risk of stroke has been well established; however, the frequency of anticoagulation therapy uses is unknown in our community. This study aims to evaluate the frequency of anticoagulation therapy and its different types among patients with atrial fibrillation.
Methods: In this cross-sectional study between April 2015 to April 2016 (before the Covid-19 pandemic), a number of 200 patients with non-valvular atrial fibrillation, in two groups of 100 patients with and without recent embolic events were studied who were hospitalized in Al-Zahra hospital in Isfahan. The CHA2DS2-VASc score and the amount and type of anticoagulant usage were evaluated in each group.
Findings: In included 200 patients (mean age 70 years, 55% women), hypertension and diabetes were the most prevalent diseases. There was no significant difference in the mean of the CHA2DS2-VASc score between the two groups; 3.8 vs 3.6. (P > 0.05). There was a history of anticoagulant use in 48% of the patients hospitalized without embolic events and a mean CHA2DS2-VASc score: of 3.6.
Conclusion: About half of the hospitalized patients without embolic events and one-third of the patients with embolic events took anticoagulants for thromboembolic prevention, mostly warfarin. In patients with atrial fibrillation, despite the need to receive anticoagulants to prevent stroke, including people with a high CHA2DS2-VASc score, the consumption of direct thrombin inhibitors was seen at a very low level.

Keywords

References

  1. Members WG, January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74(1): 104-32.
  2. Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace 2021; 23(10): 1612-76.
  3. Link MS, Giugliano RP, Ruff CT, Scirica BM, Huikuri H, Oto A, et al. Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48). Circulation: Arrhythmia and Electrophysiology 2017; 10(1): e004267.
  4. Oduah EI, Linhardt RJ, Sharfstein ST. Heparin: past, present, and future. Pharmaceuticals 2016; 9(3): 38.
  5. Mulloy B, Hogwood J, Gray E, Lever R, Page CP. Pharmacology of heparin and related drugs. Pharmacol Rev 2016; 68(1): 76-141.
  6. Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 2007; 100(9): 1419-26.
  7. Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, et al. Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation. Heart 2017; 103(8): 623-8.
  8. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;
    365(10): 883-91.
  9. Olesen JB, Lip GY, Kamper A-L, Hommel K, Køber L, Lane DA, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 2012; 367(7): 625-35.
  10. Stoica MC, Gáll Z, Gliga ML, Căldăraru CD, Székely O. Oral anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease. Medicina (Kaunas) 2021; 57(5): 422.
  11. Heidarali M, Bakhshandeh H, Golpira R, Fazelifar A, Alizadeh‐Diz A, Emkanjoo Z, et al. A prospective survey of atrial fibrillation management in Iran: Baseline results of the Iranian Registry of Atrial Fibrillation (IRAF). Int J Clin Pract 2021; 75(8): e14313.
  12. Bartholomay E, Polli I, Borges AP, Kalil C, Arroque A, Kohler I, et al. Prevalence of oral anticoagulation in atrial fibrillation. Clinics (Sao Paulo) 2014; 69(9): 615-20.
  13. Cowan C, Healicon R, Robson I, Long WR, Barrett J, Fay M, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 2013; 99(16): 1166-72.
  14. Grymonprez M, De Backer TL, Capiau A, Vauterin D, Mehuys E, Boussery K, et al. Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study. Br J Clin Pharmacol 2023; 89(4): 1360-73.
  15. Pokorney SD, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, et al. Patients’ time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. Am Heart J 2015; 170(1): 141-8. e1.
  16. Golenkina EA, Galkina SI, Pletjushkina O, Chernyak B, Gaponova TV, Romanova YM, et al. Gram-negative bacteria Salmonella typhimurium boost leukotriene synthesis induced by chemoattractant fMLP to stimulate neutrophil swarming. Front Pharmacol 2022; 12: 814113.
Journal of Isfahan Medical School
Volume 40, Issue 703
3rd Week, March
March and April 2023
Pages 1103-1108

Files

History

  • Receive Date: 26 March 2022
  • Accept Date: 06 March 2023

Share

How to cite

Statistics